Your browser doesn't support javascript.
loading
Predicting Hypertension Subtypes with Machine Learning Using Targeted Metabolites and Their Ratios.
Reel, Smarti; Reel, Parminder S; Erlic, Zoran; Amar, Laurence; Pecori, Alessio; Larsen, Casper K; Tetti, Martina; Pamporaki, Christina; Prehn, Cornelia; Adamski, Jerzy; Prejbisz, Aleksander; Ceccato, Filippo; Scaroni, Carla; Kroiss, Matthias; Dennedy, Michael C; Deinum, Jaap; Eisenhofer, Graeme; Langton, Katharina; Mulatero, Paolo; Reincke, Martin; Rossi, Gian Paolo; Lenzini, Livia; Davies, Eleanor; Gimenez-Roqueplo, Anne-Paule; Assié, Guillaume; Blanchard, Anne; Zennaro, Maria-Christina; Beuschlein, Felix; Jefferson, Emily R.
Afiliación
  • Reel S; Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee DD2 4BF, UK.
  • Reel PS; Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee DD2 4BF, UK.
  • Erlic Z; Diabetologie und Klinische Ernährung, Klinik für Endokrinologie, UniversitätsSpital Zürich (USZ) und Universität Zürich (UZH), CH-8091 Zurich, Switzerland.
  • Amar L; Université Paris Cité, INSERM, PARCC, F-75015 Paris, France.
  • Pecori A; Unité Hypertension Artérielle, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, F-75015 Paris, France.
  • Larsen CK; Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino, 10124 Torino, Italy.
  • Tetti M; Université Paris Cité, INSERM, PARCC, F-75015 Paris, France.
  • Pamporaki C; Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino, 10124 Torino, Italy.
  • Prehn C; Department of Medicine III, Universitätsklinikum Carl Gustav Carus, Technische Universität, 01307 Dresden, Germany.
  • Adamski J; Metabolomics and Proteomics Core (MPC), Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany.
  • Prejbisz A; Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany.
  • Ceccato F; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, Singapore 117597, Singapore.
  • Scaroni C; Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia.
  • Kroiss M; Department of Hypertension, National Institute of Cardiology, 04-628 Warsaw, Poland.
  • Dennedy MC; UOC Endocrinologia, Dipartimento di Medicina DIMED, Azienda Ospedaliera-Università di Padova, 35128 Padua, Italy.
  • Deinum J; UOC Endocrinologia, Dipartimento di Medicina DIMED, Azienda Ospedaliera-Università di Padova, 35128 Padua, Italy.
  • Eisenhofer G; Clinical Chemistry and Laboratory Medicine, Core Unit Clinical Mass Spectrometry, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.
  • Langton K; Schwerpunkt Endokrinologie/Diabetologie, Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, 97080 Würzburg, Germany.
  • Mulatero P; Comprehensive Cancer Center Mainfranken, Universität Würzburg, 97070 Würzburg, Germany.
  • Reincke M; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, 80336 Munich, Germany.
  • Rossi GP; The Discipline of Pharmacology and Therapeutics, School of Medicine, National University of Ireland 33 Galway, H91 TK33 Galway, Ireland.
  • Lenzini L; Department of Medicine, Section of Vascular Medicine, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands.
  • Davies E; Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Universitätsklinikum Carl Gustav Carus, 01307 Dresden, Germany.
  • Gimenez-Roqueplo AP; Department of Medicine III and Institute of Clinical Chemistry and Laboratory Medicine, Universitätsklinikum Carl Gustav Carus, 01307 Dresden, Germany.
  • Assié G; Division of Internal Medicine and Hypertension Unit, Department of Medical Sciences, University of Torino, 10124 Torino, Italy.
  • Blanchard A; Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, LMU München, 80336 Munich, Germany.
  • Zennaro MC; Internal & Emergency Medicine, ESH Specialized Hypertension Center, Department of Medicine-DIMED, University of Padua, 35128 Padua, Italy.
  • Beuschlein F; Internal & Emergency Medicine, ESH Specialized Hypertension Center, Department of Medicine-DIMED, University of Padua, 35128 Padua, Italy.
  • Jefferson ER; Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK.
Metabolites ; 12(8)2022 Aug 16.
Article en En | MEDLINE | ID: mdl-36005627
ABSTRACT
Hypertension is a major global health problem with high prevalence and complex associated health risks. Primary hypertension (PHT) is most common and the reasons behind primary hypertension are largely unknown. Endocrine hypertension (EHT) is another complex form of hypertension with an estimated prevalence varying from 3 to 20% depending on the population studied. It occurs due to underlying conditions associated with hormonal excess mainly related to adrenal tumours and sub-categorised primary aldosteronism (PA), Cushing's syndrome (CS), pheochromocytoma or functional paraganglioma (PPGL). Endocrine hypertension is often misdiagnosed as primary hypertension, causing delays in treatment for the underlying condition, reduced quality of life, and costly antihypertensive treatment that is often ineffective. This study systematically used targeted metabolomics and high-throughput machine learning methods to predict the key biomarkers in classifying and distinguishing the various subtypes of endocrine and primary hypertension. The trained models successfully classified CS from PHT and EHT from PHT with 92% specificity on the test set. The most prominent targeted metabolites and metabolite ratios for hypertension identification for different disease comparisons were C181, C182, and Orn/Arg. Sex was identified as an important feature in CS vs. PHT classification.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Metabolites Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 2_ODS3 Problema de salud: 2_cobertura_universal Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Idioma: En Revista: Metabolites Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido
...